Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024, at 8:55 a.m. PT (11:55 a.m. ET).
弗吉尼亞州夏洛茨維爾，2024年5月8日（GLOBE NEWSWIRE）——Acumen Pharmicals, Inc.（納斯達克股票代碼：ABOS）是一家臨床階段的生物製藥公司，正在開發一種針對治療阿爾茨海默氏病的毒性可溶性β澱粉樣低聚物的新療法。該公司今天宣佈，管理層將在2024年5月15日星期三參加2024年美國銀行醫療保健會議的爐邊談話。太平洋時間上午 8:55（美國東部時間上午 11:55）。
The live webcast may be accessed under the Investors tab on and will be archived for 90 days.
可以在投資者選項卡下訪問網絡直播，並將存檔90天。
About Acumen Pharmaceuticals, Inc.
關於 Acumen 製藥公司
Acumen, headquartered in Charlottesville, VA, with additional offices in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, following positive results in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer's disease patients. For more information, visit .
Acumen總部位於弗吉尼亞州夏洛茨維爾，在印第安納州印第安納波利斯和馬薩諸塞州牛頓設有辦事處，是一家臨床階段的生物製藥公司，正在開發一種針對毒性可溶性β澱粉樣低聚物（AβO）的新療法，用於治療阿爾茨海默氏病（AD）。Acumen的科學創始人開創了對AβOS的研究，越來越多的證據表明AβOS是阿爾茨海默病病理學的早期和持續誘因。繼涉及早期阿爾茨海默氏病患者的1期臨床試驗INTERCT-AD取得積極結果之後，Acumen目前正專注於推進其候選研究產品sabirnetug（ACU193），這是一種選擇性靶向毒性可溶性AβO的人源化單克隆抗體。欲了解更多信息，請訪問。
Investors:
Alex Braun
abraun@acumenpharm.com
投資者：
亞歷克斯·布勞恩
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
媒體：
AcumenPR@westwicke.com
譯文內容由第三人軟體翻譯。